ResearchMoz

Paclical (Ovarian Cancer) Analysis and Forecasts to 2020

Publisher Name » GlobalData
Published Date » 2011-10-20
No. Of Pages » 33

Summary

GlobalDatas pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Paclical sales estimates for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope
  • Therapy area profile including patient population for the US and EU5
  • Analysis and review of Paclical including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Paclical including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Paclical in the US and EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7

3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11

4 TumorNodeMetastases (TNM) Classification of Ovarian Cancer 12

5 Paclical 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 Phase I/II trial 15
5.3.2 Phase III trial 15
5.3.3 Results 16
5.4 Trial History of Paclical 16
5.5 Factors affecting sales of Paclical 16
5.5.1 Advantage over Taxol 16
5.5.2 Reduced Side Effects 16
5.5.3 New Generation Drug 16
5.5.4 Niche Market 17
5.5.5 Orphan Drug Designation in US and in Europe 17
5.5.6 Blockbuster potential with additional indications 17
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of competition 18
5.7 Sales Forecasts 18
5.7.1 Target patient pool of Paclical 19
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual cost of Therapy 20
5.7.5 Sales Projections of Paclical 21

6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 List of Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 33
6.6 Sources 33

List of Tables


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Trial History of Paclical 16
Table 5: Drug Risk Benefit Score of Paclical 17
Table 6: Estimated Annual Cost of Therapy of Paclical, 2012 20
Table 7: Paclical, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 21
Table 8: Paclical, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 22
Table 9: Paclical, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 23
Table 10: Paclical, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 24
Table 11: Paclical, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 25
Table 12: Paclical, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 26
Table 13: Paclical, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 27

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 20082030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 20082030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 20082030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Paclical 19
Figure 9: Paclical, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 21
Figure 10: Paclical, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 22
Figure 11: Paclical, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 23
Figure 12: Paclical, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 24
Figure 13: Paclical, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 25
Figure 14: Paclical, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 26
Figure 15: Paclical, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 27
Figure 16: Paclical, Ovarian Cancer, The US and EU5, Sales Distribution (%), 2019 28
Figure 17: Drug Model Diagram 31
Figure 18: Patients Approved for the Drug 31

Upcoming Reports:

Still Drinks Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Description Still drinks refers to drinks that include ready-to-drink fruit or non-fruit that typically contains juice content of lower than 25 percent, and water is also included in this sweetened flavor. Generally, in most countries consumers don’t tend to distinguish between juices, nectars, and the still drinks. It’s mostly the price that determines the consumer buying rather than the juice content. Of all the categories under the soft drinks, the still drinks market has shown continual growth with volumes advancing by almost close to 7% which is highest after...
Food Processing Machinery Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The food processing machinery market is witnessing tremendous growth with the increasing demand from food, beverage, pharmaceuticals, and personal care industries. With increasing competition in the food processing machinery industry, manufacturers are striving to offer broader range of products at lower costs along with value-added engineering, design, and other services.  Other significant market drivers include   Recovery from economic slowdown Rising food and beverage shipments Introduction of new products in the market Acceleration in non...
Biotechnology Reagents Market - Global Industry Size, Share, Trends, Analysis and Forecast, 2011 - 2018
By - Transparency Market Research
Biotechnology reagents are the substances or chemical compound that is added to a system to detect, examine or synthesize other substances. Biotechnology industry mainly combines cellular and molecular biotechnology, human immunology and genetics, focusing mainly upon research and innovations in recombinant DNA technology or genetic engineering. Growth of such industries mainly depends on innovative products. Hence, all this attributes growth opportunities for related markets such as reagents, which depends to a large extent on the market for biotechnology industries. Some of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...